Market News
Stay updated with the latest market trends, earnings, and economic indicators.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.

Sensex Today | Stock Market LIVE Updates: GIFT Nifty extends losses to 200 points; Lenskart in focus
Sensex Today | Stock Market LIVE Updates: The bulls may take comfort from the fact that all recent selling has seen a reversal around this 23,250 - 23,350 range. A break of that level risks further downside for the index. Same is the case with the Nifty Bank, which had another 1,000-point range trading day on Monday.
Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer
Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led gains. Midcap and smallcap indices saw small gains.

Top Gainers & Losers on May 18: Gland Pharma, Coforge, PB Fintech, BSE, Voltas, Bharti Airtel among top gainers
Indian stocks marginally gained on May 18, driven by strong tech buying and pharma support, with Nifty 50 up 0.03% at 23,649 and BSE Sensex at 75,263. However, the broader market faced pressure as Nifty Midcap 100 and Nifty Smallcap 100 fell.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
Cigniti Tech exits Nifty indices following amalgamation with Coforge
As part of the changes, Cigniti Technologies will be removed from the Nifty Microcap 250 index and replaced by Sanofi Consumer Healthcare India.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weakness
Smallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 earnings. While Nifty 50 slipped below 24,000 amid global concerns, improving momentum and technical indicators signal potential continued strength in the smallcap segment, according to Emkay.
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.